Ann: Compelling Preclinical Breast Cancer Results, page-4

ASX Announcement (pg 1):

Compelling Preclinical Breast Cancer Results

§ Bisantrene killed breast cancer cells resistant to the current standard of care
breast cancer drugs etoposide, palbocicclib, fulvestrant, tamoxifen, doxorubicin,
epirubicin and cyclophosphamide
§ Bisantrene was found to kill breast cancer cells from all common breast cancer
subtypes including triple negative, ER+, and Her2+
§ These results clearly support advancing Bisantrene into human breast cancer
clinical trials

9 March 2021 – Race Oncology Limited (ASX: RAC) is pleased to share the final results of
our collaborative preclinical research program with the eminent cancer researcher,
Associate Professor Nikki Verrills of The University of Newcastle and Hunter Medical
Research Institute.

The aim of this research program was to identify combinations of existing breast cancer
drugs which when paired with Bisantrene show equivalent or better efficacy to existing
treatment options, but with reduced side effects. Activity of Bisantrene alone against a
range of breast cancer genetic subtypes, including those resistant to standard of care
drug treatments, was also explored.

The interim results demonstrated that Bisantrene was an effective chemotherapeutic
agent across a wide range of genetically distinct breast cancer subtypes (ASX
announcement: 24 Nov 2020). Bisantrene was able to kill some cancer subtypes that
were resistant to the currently used anthracyclines doxorubicin and epirubicin.
Importantly, Bisantrene showed near identical additive benefit when used in
combination with cyclophosphamide to that seen with either doxorubicin or epirubicin.
Final results showed Bisantrene to be an effective chemotherapeutic agent across a
diverse panel of genetically defined breast cancer subtypes and to also kill breast
cancer cells resistant to a wide range of breast cancer treatment drugs.

Race’s CSO Dr Daniel Tillett commented “The final results from Nikki’s team highlights
Bisantrene’s potential use in breast cancers resistant to current treatments. Not only does
Bisantrene offer a potentially safer alternative to existing chemotherapeutic drugs, it may
also help patients who have exhausted other treatment options.”

Race’s CEO Mr Phillip Lynch added, “This new research underscores our confidence in
moving Bisantrene into Phase II breast cancer trials and continues to build on the body of
evidence we have supporting Bisantrene’s broader applications. Our aim here is to bring a
valuable new treatment forward for the management of breast cancer.”